| 张 颖,张英丽,张 平.晚期卵巢癌新辅助化疗的研究进展[J].肿瘤学杂志,2014,20(11):942-946. |
| 晚期卵巢癌新辅助化疗的研究进展 |
| Progress in Neoadjuvant Chemotherapy in the Treatment for Advanced Ovarian Cancer |
| 投稿时间：2014-08-30 |
| DOI：10.11735/j.issn.1671-170X.2014.11.B014 |
|
 |
| 中文关键词: 新辅助化疗 卵巢肿瘤 细胞减灭术 |
| 英文关键词:neoadjuvant chemotherapy ovarian neoplasms primary debulking surgery |
| 基金项目:浙江省自然科学基金（Y2111317） |
|
| 摘要点击次数: 2001 |
| 全文下载次数: 973 |
| 中文摘要: |
| 摘 要：卵巢癌是死亡率最高的妇科恶性肿瘤之一，约70%患者确诊时已属Ⅲ~Ⅳ期，预后较差。目前标准的治疗方式是理想初始肿瘤细胞减灭术，术后辅以铂类联合紫杉醇类化疗。对于病灶难以切除的晚期卵巢癌患者而言，可以选择术前新辅助化疗以提高满意减瘤术的手术机率。本文对晚期卵巢癌新辅助化疗的研究进展进行综述。 |
| 英文摘要: |
| Abstract：Ovarian cancer is one of the gynecological malignancies with the highest mortality rate. Approximately 70% patients are diagnosed at advanced stages of the disease，for which the prognosis is generally poor. Optimal primary debulking surgery(PDS) followed by platinum-based chemotherapy is the standard treatment. For advanced patients with unresectable lesions，neoadjuvant chemotherapy(NACT) is a way to improve the rate of cytoreductive surgery. This article reviews the progress in NACT in the treatment for advanced ovarian cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|